#South Korea #Seoul #Lunit #Digital Pathology #CellCarta

Lunit and CellCarta: A New Era in Clinical Trials

In a groundbreaking move, Lunit, a frontrunner in AI technology for cancer diagnostics, has formed a significant alliance with CellCarta, a prominent contract research organization (CRO). This collaboration marks a pivotal step forward in the integration of digital pathology AI into clinical trial workflows worldwide.

A Partnership of Excellence

Lunit, which operates under the ticker KRX:328130.KQ, has become well-known for its contributions to oncology by leveraging artificial intelligence to enhance cancer diagnostics and therapies. Their latest venture with CellCarta illustrates a collective goal—to provide biopharmaceutical companies with advanced AI-powered tools directly applicable to clinical research.

CellCarta, which is recognized for its high standards in laboratory services and clinical trial support across North America, Europe, and Asia, brings extensive experience to the table. The organization has participated in over 1,000 clinical studies, including 75 phase III PMA trials, thereby establishing a track record of reliability and expertise.

The Role of AI in Clinical Trials

The collaboration between Lunit and CellCarta aims to incorporate Lunit's AI pathology solutions within CellCarta’s services. This integration is set to streamline processes, making it significantly easier for pharmaceutical sponsors to adopt AI-driven analyses into their existing workflows. More importantly, it allows for more precise characterization of tumor biology through the analysis of histological and immunohistochemical whole slide images.

While the technology promises to accelerate drug discovery and development through better patient stratification and biomarker evolution, it also lays the groundwork for advancing precision oncology practices. The dual commitment of both organizations—Lunit's expertise in AI analysis and CellCarta's mastery of immunology and histopathology—will potentially transform how tumors are evaluated and treated, ultimately improving patient outcomes.

Expanding Accessibility to Innovative Solutions

Lunit's SCOPE® suite, comprising AI tools like SCOPE IO, SCOPE PD-L1, and SCOPE uIHC, will now be more accessible to a wider audience through this partnership. These tools enable quantitative analysis and classification of immune phenotypes, aiding in the identification of patients who may benefit from specific therapeutic interventions. This holistic approach to data capture provides clinical trial teams with scalable insights that inform treatment decisions and enhance drug development processes.

Yannick Waumans, Director of Digital Pathology Solutions at CellCarta, noted the growing demand among biopharma companies for efficient and validated solutions. With the partnership, he underscores that clients will gain a powerful AI platform that integrates seamlessly into global clinical workflows, enabling timely biomarker development and patient selection strategies.

Looking Ahead: The Future of Oncology Trials

Reflecting on the partnership, Brandon Suh, CEO of Lunit, expressed enthusiasm over collaborating with CellCarta, citing its leadership in digital pathology deployment. He believes that this partnership will empower clinical research teams to effectively exploit AI in pathology. This alliance illuminates a path forward as clinical trials continue to evolve with the support of innovative technologies.

This past June, Lunit exemplified the potential of its AI-powered platform during a workshop at CellCarta’s Antwerp site. Presentations highlighted numerous applications for deep learning in the fields of tumor microenvironment profiling and biomarker quantification across various cancer types.

About the Companies

Founded in 2013, Lunit has rapidly become a leader in cancer diagnostics powered by artificial intelligence. Their FDA-cleared Lunit INSIGHT suite currently aids in cancer screenings across over 7,000 medical facilities in more than 65 countries, demonstrating a worldwide commitment to confronting cancer.

CellCarta, on the other hand, stands out as a CRO that provides intricate biomarker testing services, having attained high standards of CAP accreditations and CLIA certifications globally. This platform empowers pharmaceutical partners through comprehensive support throughout all stages of drug discovery.

In summary, the alliance between Lunit and CellCarta not only turns the page toward innovative solutions in clinical trials but also lays the groundwork for significant advancements in patient care. As the healthcare sector embraces AI more robustly, the impact of such partnerships can redefine how cancer therapies are developed and delivered in the landscape of modern medicine.